These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33586650)

  • 1. Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma.
    Russo I; Filoni A; Alaibac M
    Eur J Dermatol; 2021 Feb; 31(1):99-100. PubMed ID: 33586650
    [No Abstract]   [Full Text] [Related]  

  • 2. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
    Prescrire Int; 2017 May; 26(182):118-119. PubMed ID: 30730667
    [No Abstract]   [Full Text] [Related]  

  • 3. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
    Thiem A; Kneitz H; Schummer P; Herz S; Schrama D; Houben R; Goebeler M; Schilling B; Gesierich A
    Acta Derm Venereol; 2017 Nov; 97(10):1252-1254. PubMed ID: 28761962
    [No Abstract]   [Full Text] [Related]  

  • 4. Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia.
    Arenbergerova M; Fialova A; Arenberger P; Gkalpakiotis S; Jirasek T; Srp A; Novotna A; Frankova H
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e72-e74. PubMed ID: 28833722
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treating metastatic melanoma: Risk management].
    Lebbe C; Robert C
    Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
    [No Abstract]   [Full Text] [Related]  

  • 6. Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab.
    Gracia-Cazaña T; Padgett E; Hernández-García A; Sánchez-Salas MP
    Dermatol Online J; 2019 Dec; 25(12):. PubMed ID: 32045170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
    Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
    Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
    [No Abstract]   [Full Text] [Related]  

  • 8. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study.
    Chang ALS; Tran DC; Cannon JGD; Li S; Jeng M; Patel R; Van der Bokke L; Pague A; Brotherton R; Rieger KE; Satpathy AT; Yost KE; Reddy S; Sarin K; Colevas AD
    J Am Acad Dermatol; 2019 Feb; 80(2):564-566. PubMed ID: 30145186
    [No Abstract]   [Full Text] [Related]  

  • 9. Deceleration in the rate of keratinocyte cancers and precancerous lesions during programmed death-1 inhibition therapy for advanced melanoma, with recrudescence on discontinuation.
    Roche L; Moriarty B; Fabre A; Crowne J; Lally A
    Clin Exp Dermatol; 2022 Mar; 47(3):582-584. PubMed ID: 34633688
    [No Abstract]   [Full Text] [Related]  

  • 10. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
    Hribernik N; Boc M; Ocvirk J; Knez-Arbeiter J; Mesti T; Ignjatovic M; Rebersek M
    Radiol Oncol; 2020 Jan; 54(1):119-127. PubMed ID: 31955148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digital ischemia triggered by coronavirus disease 2019 in a patient under cemiplimab treatment.
    Serra-García L; Bosch-Amate X; Alamon-Reig F; Giavedoni P; Fuertes I; Morgado-Carrasco D; Iglesias P; Puig S; Mascaró JM
    Int J Dermatol; 2021 Jan; 60(1):e30-e32. PubMed ID: 33040324
    [No Abstract]   [Full Text] [Related]  

  • 12. CorrespondenceMetastatic basal cell carcinoma with neuroendocrine differentiation: complete response to cemiplimab.
    Marti-Marti I; Puig S; Albero-González R; Masferrer E; Iglesias P; Pérez-Anker J; Serra-García L; Tarroch X; Curcó N; Toll A
    Clin Exp Dermatol; 2024 Aug; 49(9):1060-1062. PubMed ID: 38494790
    [No Abstract]   [Full Text] [Related]  

  • 13. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S; Ieremia E; Matin RN
    Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
    [No Abstract]   [Full Text] [Related]  

  • 14. The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma.
    Hanna DL; Law SJ; Merrick SA; Heptinstall L; Bass P; Dupont P; Sheri A
    Melanoma Res; 2020 Jun; 30(3):321-324. PubMed ID: 31764435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
    Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
    JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevention of amputation by neoadjuvant therapy with pembrolizumab in acrolentiginous melanoma.
    Hansen I; Rünger A; Noebel C; Geidel G; Kött J; Menz A; Hildebrandt L; Schneider SW; Gebhardt C
    J Eur Acad Dermatol Venereol; 2024 Sep; 38(9):e820-e822. PubMed ID: 38421077
    [No Abstract]   [Full Text] [Related]  

  • 17. Pembrolizumab-Induced Alopecia Areata.
    Elshimy N; Blakeway E; Mitra A
    Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
    [No Abstract]   [Full Text] [Related]  

  • 18. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
    Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
    Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
    [No Abstract]   [Full Text] [Related]  

  • 19. Diffuse Hepatic Infiltration by Metastatic Melanoma.
    Velázquez HE; Castro-Alonso FJ; Bourlon C; Gabutti A; Gallegos C; Bourlon MT
    Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365754
    [No Abstract]   [Full Text] [Related]  

  • 20. A case of ruptured hepatic metastases during pembrolizumab administration for cutaneous malignant melanoma.
    Igari S; Yamamoto M; Kikuchi N; Ohtsuka M; Yamamoto T
    An Bras Dermatol; 2024; 99(3):450-451. PubMed ID: 38307808
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.